Treating Acute Covid-19—Final Chapters Still Unwritten
RT Gandhi, M Hirsch - New England Journal of Medicine, 2024 - Mass Medical Soc
Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …
[HTML][HTML] Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo …
Q Cheng, J Chen, Q Jia, Z Fang, G Zhao - Aging (albany NY), 2021 - ncbi.nlm.nih.gov
Background: Many recent studies have investigated the role of drug interventions for
coronavirus disease 2019 (COVID-19) infection. However, an important question has been …
coronavirus disease 2019 (COVID-19) infection. However, an important question has been …
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
H Bian, ZH Zheng, D Wei, Z Zhang, WZ Kang, CQ Hao… - medrxiv, 2020 - medrxiv.org
Background SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs.
It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 …
It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 …
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
D Jochmans, C Liu, K Donckers, A Stoycheva… - MBio, 2023 - Am Soc Microbiol
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle
and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors …
and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors …
[HTML][HTML] The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis
K Rahmani, R Shavaleh, M Forouhi… - Frontiers in public …, 2022 - frontiersin.org
Background Vaccination, one of the most important and effective ways of preventing
infectious diseases, has recently been used to control the COVID-19 pandemic. The present …
infectious diseases, has recently been used to control the COVID-19 pandemic. The present …
Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy
Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA-approved
drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have …
drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have …
In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery.
Z Wang, L Yang - Journal of medical virology, 2022 - search.ebscohost.com
Since the outbreak of COVID-19, caused by the SARS-CoV-2, in December 2019, the
ongoing pandemic has posed 5 318 216 deaths worldwide. 1 Vaccines, traditional Chinese …
ongoing pandemic has posed 5 318 216 deaths worldwide. 1 Vaccines, traditional Chinese …
[HTML][HTML] Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …
[HTML][HTML] Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge
Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
K Vandyck, J Deval - Current opinion in virology, 2021 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-
19 pandemic. The coronavirus 3-chymotrypsin-like protease (3CLpro) controls virus …
19 pandemic. The coronavirus 3-chymotrypsin-like protease (3CLpro) controls virus …